Intravenous Pamidronate Therapy in Taiwanese Patients with Osteogenesis Imperfecta
Information on the long-term efficacy of intravenous pamidronate therapy in Asian patients with osteogenesis imperfecta (OI) is limited. We report our experience using pamidronate in Taiwanese patients with OI. Methods: Twenty-six patients with type I, III, or IV OI (eight males and 18 females; age...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2008-10-01
|
| Series: | Pediatrics and Neonatology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1875957209600024 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849323323016609792 |
|---|---|
| author | Hsiang-Yu Lin Shuan-Pei Lin Chih-Kuang Chuang Ming-Ren Chen Chia-Ying Chang |
| author_facet | Hsiang-Yu Lin Shuan-Pei Lin Chih-Kuang Chuang Ming-Ren Chen Chia-Ying Chang |
| author_sort | Hsiang-Yu Lin |
| collection | DOAJ |
| description | Information on the long-term efficacy of intravenous pamidronate therapy in Asian patients with osteogenesis imperfecta (OI) is limited. We report our experience using pamidronate in Taiwanese patients with OI.
Methods: Twenty-six patients with type I, III, or IV OI (eight males and 18 females; age range at last follow-up, 2.9-39.2 years) who received (or were currently receiving) intravenous pamidronate treatment (30 mg/m2/dose, every month) were retrospectively analyzed. Patients were followed for 1.0-7.3 years over the study period from February 2000 to October 2007.
Results: The mean standard deviation score (SDS) for bone mineral density (BMD) had increased significantly from −4.72 to −3.37 (p < 0.005) after 1 year of treatment. In 16 patients evaluated after 4 years and eight after 6 years, the mean SDS continued to improve, to −2.69 (p < 0.001) and −1.54 (p < 0.005), respectively. The fracture rate decreased significantly (from 2.8 ± 1.1 to 0.6 ± 0.6, p < 0.001), and nine patients (35%) had no fractures while receiving treatment. The response to pamidronate was significantly better in patients with poorer initial BMD SDS (1 year: r = −0.71, p < 0.01; 4 years: r = −0.81, p < 0.01).
Conclusion: This retrospective study suggests that Taiwanese patients with OI can benefit from pamidronate treatment, leading to a reduced incidence of fractures and increased BMD, especially in patients with poor baseline BMD. |
| format | Article |
| id | doaj-art-72a5da9b7bec4fd48ffc789394ae30ea |
| institution | Kabale University |
| issn | 1875-9572 |
| language | English |
| publishDate | 2008-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Pediatrics and Neonatology |
| spelling | doaj-art-72a5da9b7bec4fd48ffc789394ae30ea2025-08-20T03:49:04ZengElsevierPediatrics and Neonatology1875-95722008-10-0149516116510.1016/S1875-9572(09)60002-4Intravenous Pamidronate Therapy in Taiwanese Patients with Osteogenesis ImperfectaHsiang-Yu Lin0Shuan-Pei Lin1Chih-Kuang Chuang2Ming-Ren Chen3Chia-Ying Chang4Department of Pediatrics, Mackay Memorial Hospital, Taipei, TaiwanDepartment of Pediatrics, Mackay Memorial Hospital, Taipei, TaiwanDepartment of Medical Research, Mackay Memorial Hospital, Taipei, TaiwanDepartment of Pediatrics, Mackay Memorial Hospital, Taipei, TaiwanDepartment of Pediatrics, Mackay Memorial Hospital, Taipei, TaiwanInformation on the long-term efficacy of intravenous pamidronate therapy in Asian patients with osteogenesis imperfecta (OI) is limited. We report our experience using pamidronate in Taiwanese patients with OI. Methods: Twenty-six patients with type I, III, or IV OI (eight males and 18 females; age range at last follow-up, 2.9-39.2 years) who received (or were currently receiving) intravenous pamidronate treatment (30 mg/m2/dose, every month) were retrospectively analyzed. Patients were followed for 1.0-7.3 years over the study period from February 2000 to October 2007. Results: The mean standard deviation score (SDS) for bone mineral density (BMD) had increased significantly from −4.72 to −3.37 (p < 0.005) after 1 year of treatment. In 16 patients evaluated after 4 years and eight after 6 years, the mean SDS continued to improve, to −2.69 (p < 0.001) and −1.54 (p < 0.005), respectively. The fracture rate decreased significantly (from 2.8 ± 1.1 to 0.6 ± 0.6, p < 0.001), and nine patients (35%) had no fractures while receiving treatment. The response to pamidronate was significantly better in patients with poorer initial BMD SDS (1 year: r = −0.71, p < 0.01; 4 years: r = −0.81, p < 0.01). Conclusion: This retrospective study suggests that Taiwanese patients with OI can benefit from pamidronate treatment, leading to a reduced incidence of fractures and increased BMD, especially in patients with poor baseline BMD.http://www.sciencedirect.com/science/article/pii/S1875957209600024bisphosphonatesbone mineral densityfractureosteogenesis imperfectapamidronate |
| spellingShingle | Hsiang-Yu Lin Shuan-Pei Lin Chih-Kuang Chuang Ming-Ren Chen Chia-Ying Chang Intravenous Pamidronate Therapy in Taiwanese Patients with Osteogenesis Imperfecta Pediatrics and Neonatology bisphosphonates bone mineral density fracture osteogenesis imperfecta pamidronate |
| title | Intravenous Pamidronate Therapy in Taiwanese Patients with Osteogenesis Imperfecta |
| title_full | Intravenous Pamidronate Therapy in Taiwanese Patients with Osteogenesis Imperfecta |
| title_fullStr | Intravenous Pamidronate Therapy in Taiwanese Patients with Osteogenesis Imperfecta |
| title_full_unstemmed | Intravenous Pamidronate Therapy in Taiwanese Patients with Osteogenesis Imperfecta |
| title_short | Intravenous Pamidronate Therapy in Taiwanese Patients with Osteogenesis Imperfecta |
| title_sort | intravenous pamidronate therapy in taiwanese patients with osteogenesis imperfecta |
| topic | bisphosphonates bone mineral density fracture osteogenesis imperfecta pamidronate |
| url | http://www.sciencedirect.com/science/article/pii/S1875957209600024 |
| work_keys_str_mv | AT hsiangyulin intravenouspamidronatetherapyintaiwanesepatientswithosteogenesisimperfecta AT shuanpeilin intravenouspamidronatetherapyintaiwanesepatientswithosteogenesisimperfecta AT chihkuangchuang intravenouspamidronatetherapyintaiwanesepatientswithosteogenesisimperfecta AT mingrenchen intravenouspamidronatetherapyintaiwanesepatientswithosteogenesisimperfecta AT chiayingchang intravenouspamidronatetherapyintaiwanesepatientswithosteogenesisimperfecta |